Medicare delayed a plan to make insurance companies cover GLP-1 drugs Wegovy and Zepbound. Instead, Medicare will cover the popular weight-loss drugs ...
The Trump administration had planned for insurers to provide cheap weight loss drugs to seniors through a Medicare pilot program. Insurers said no, so the government will instead cover the drugs ...
Medicare has delayed its BALANCE program for weight-loss drugs like Wegovy. Discover the new 'bridge program' that will offer coverage for a $50 copay starting in 2026.
Medicare currently covers GLP-1s to treat conditions like Type 2 diabetes. It will begin covering the drug for weight loss with prior authorization beginning in July 2026. It'll be up to Part D plan ...
Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for their weight management indications for people with obesity, President Trump announced on Thursday. "Until now, neither of these ...
Medicare Medicare is federal health insurance for people 65 or older, and some people under 65 with certain disabilities or conditions. A federal agency called the Centers for Medicare & Medicaid Services runs Medicare. Because it’s a federal program, Medicare has set standards for costs and coverage. This means a person’s Medicare coverage will be the same no matter what state they live in.
USA TODAY on MSN: GLP-1 weight-loss drugs will still be cheap with Medicare, but there's a catch
GLP-1 weight-loss drugs will still be cheap with Medicare, but there's a catch
By Mariam Sunny April 22 (Reuters) - A delay in a Medicare pilot to cover obesity drugs due to health insurers' hesitation to participate in the program is unlikely to dent near-term demand for weight ...